Matthew C. Lucas

1.0k total citations
32 papers, 530 citations indexed

About

Matthew C. Lucas is a scholar working on Molecular Biology, Organic Chemistry and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Matthew C. Lucas has authored 32 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Organic Chemistry and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Matthew C. Lucas's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Glycosylation and Glycoproteins Research (4 papers) and Synthetic Organic Chemistry Methods (4 papers). Matthew C. Lucas is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Glycosylation and Glycoproteins Research (4 papers) and Synthetic Organic Chemistry Methods (4 papers). Matthew C. Lucas collaborates with scholars based in United States, United Kingdom and Switzerland. Matthew C. Lucas's co-authors include Peter D. Howes, Seng‐Lai Tan, Cheng Liao, Julie A. DeMartino, Pravin S. Iyer, Christopher S. Stevenson, Chee Yeun Chung, Robert H. Scannevin, Kenneth J. Rhodes and Daniel F. Tardiff and has published in prestigious journals such as Cancer Research, Chemical Communications and Journal of Medicinal Chemistry.

In The Last Decade

Matthew C. Lucas

29 papers receiving 517 citations

Peers

Countries citing papers authored by Matthew C. Lucas

Since Specialization

Citations

This map shows the geographic impact of Matthew C. Lucas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew C. Lucas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew C. Lucas more than expected).

Fields of papers citing papers by Matthew C. Lucas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew C. Lucas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew C. Lucas. The network helps show where Matthew C. Lucas may publish in the future.

Co-authorship network of co-authors of Matthew C. Lucas

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew C. Lucas. A scholar is included among the top collaborators of Matthew C. Lucas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew C. Lucas. Matthew C. Lucas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 1871: Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors 2023 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Matthew C. Lucas, Charles Xing, (unknown), (unknown), (unknown), (unknown), Cathy Chang, Gerhard Frey, William J. Boyle, Jay M. Short	1
2	Current and emerging therapies for Achondroplasia: The dawn of precision medicine 2023 ·Bioorganic & Medicinal Chemistry ·Étienne Dardenne, Noboru Ishiyama, (unknown), Matthew C. Lucas	6
3	27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models 2022 ·Annals of Oncology ·Matthew C. Lucas, Melinda S. Merchant, Matthew O’Connor, Sherri Smith, Anthony F. Trombino, (unknown), (unknown), Sudharshan Eathiraj, Nigel J. Waters, Elizabeth Buck	5
4	Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease 2022 ·Molecular Neurobiology ·Daniel F. Tardiff, Matthew C. Lucas, Iwona Wrona, (unknown), Chee Yeun Chung, Bertrand Le Bourdonnec, Kenneth J. Rhodes, Robert H. Scannevin	18
5	Anti-tumor activity of BDTX-1535, an irreversible CNS penetrant inhibitor of multiple EGFR extracellular domain alterations, in preclinical glioblastoma models 2022 ·European Journal of Cancer ·Matthew C. Lucas, Melinda S. Merchant, Matthew J. O’Connor, Sherri Smith, Anthony F. Trombino, Nigel J. Waters, Sudharshan Eathiraj, (unknown), Alessandra Breschi, (unknown), (unknown), Elizabeth Buck	0
6	Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations 2022 ·European Journal of Cancer ·Pui Yee Ng, Yoon-Chi Han, Luisa Shin Ogawa, Rainer Schulz, Shao Ning Yang, (unknown), (unknown), Darlene Romashko, Andrei Salomatov, (unknown), Matthew C. Lucas, (unknown), Elizabeth Buck	1
7	35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers 2021 ·Annals of Oncology ·Étienne Dardenne, (unknown), (unknown), Shao Ning Yang, Ahmet Mentes, Luisa Shin Ogawa, (unknown), Anthony F. Trombino, Sherri Smith, Darlene Romashko, Noboru Ishiyama, (unknown), Shalabh Thakur, Edward Rosfjord, Elizabeth Buck, (unknown), Matthew C. Lucas, (unknown)	1
8	Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers 2021 ·Molecular Cancer Therapeutics ·Étienne Dardenne, Fernando Padilla, (unknown), Shao Ning Yang, Ahmet Mentes, Luisa Shin Ogawa, Anthony F. Trombino, Darlene Romashko, (unknown), Shalabh Thakur, Elisabeth Buck, Christopher Roberts, Matthew C. Lucas, (unknown)	1
9	Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity 2018 ·Cell Reports ·Benjamin Vincent, Daniel F. Tardiff, Jeff S. Piotrowski, Rebecca Aron, Matthew C. Lucas, Chee Yeun Chung, Helene Bacherman, (unknown), (unknown), (unknown), (unknown), Heather Sadlish, (unknown), (unknown), Vikram Khurana, Bertrand Le Bourdonnec, Robert H. Scannevin, Kenneth J. Rhodes	102
10	Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders 2013 ·Pharmacology & Therapeutics ·Seng‐Lai Tan, Cheng Liao, Matthew C. Lucas, Christopher S. Stevenson, Julie A. DeMartino	50
11	ROCK: the Roche medicinal chemistry knowledge application – design, use and impact 2011 ·Drug Discovery Today ·A. Mayweg, Urs Hofer, Patrick Schnider, (unknown), Guido Galley, Patrizio Mattei, Matthew C. Lucas, (unknown)	15
12	Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain 2010 ·Bioorganic & Medicinal Chemistry Letters ·Matthew C. Lucas, Robert J. Weikert, David S. Carter, Haiying Cai, Robert Greenhouse, Pravin S. Iyer, (unknown), Eun Kyung Lee, (unknown), (unknown), (unknown), Ryan C. Schoenfeld, Sandra Steiner, Yansheng Zhai, Stephen M. Lynch	15
13	Cyclic amide bioisosterism: Strategic application to the design and synthesis of HCV NS5B polymerase inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Hanbiao Yang, R. Hendricks, (unknown), (unknown), Calvin Yee, Matthew C. Lucas, Yanli Yang, Amy Fung, Sonal Rajyaguru, Seth F. Harris, Vincent Lévêque, Julie Q. Hang, Sophie Le Pogam, Deborah C. Reuter, Gisele Tavares	22
14	2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression 2010 ·Bioorganic & Medicinal Chemistry Letters ·David S. Carter, Haiying Cai, Eun Kyung Lee, Pravin S. Iyer, Matthew C. Lucas, (unknown), Ryan C. Schoenfeld, Robert J. Weikert	25
15	Novel, achiral aminoheterocycles as selective monoamine reuptake inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Matthew C. Lucas, David S. Carter, Haiying Cai, Eun Kyung Lee, Ryan C. Schoenfeld, Sandra Steiner, (unknown), Robert J. Weikert, Pravin S. Iyer	4
16	Microwave-enhanced rhodium-catalyzed conjugate-addition of aryl boronic acids to unprotected maleimides 2007 ·Tetrahedron Letters ·Pravin S. Iyer, (unknown), Matthew C. Lucas	16
17	Palladium-catalyzed, heteroatom assisted, regioselective cyclizations 2003 ·Chemical Communications ·Marie E. Krafft, Matthew C. Lucas	5
18	The first total synthesis of (±)-1-desoxyhypnophilin 2001 ·Tetrahedron ·(unknown), Matthew C. Lucas, Peter D. Howes	22
19	A thiyl radical mediated cascade sequence for the co-cyclisation of 1,6-hexadienes with sulfur atom transfer 2000 ·Tetrahedron Letters ·(unknown), (unknown), Matthew C. Lucas, (unknown), Peter D. Howes	15
20	A total synthesis of (±)-1-desoxyhypnophilin: using ring closing metathesis for the construction of cyclic enones 2000 ·Tetrahedron Letters ·(unknown), Matthew C. Lucas, Peter D. Howes	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact